Article date: February 2017
By: Byung‐Moon Choi, Yong‐Hun Lee, Sang‐Mee An, Soo‐Han Lee, Eun‐Kyung Lee, Gyu‐Jeong Noh in Volume 83, Issue 2, pages 314-325
Aims
This prospective study aimed to characterize the population pharmacokinetics of intravenous oxycodone and to determine the minimum effective concentration (MEC) and minimum effective analgesic concentration (MEAC) of oxycodone for major open intra‐abdominal surgery.
Methods
In the pharmacokinetic study, patients were administered intravenous oxycodone (0.1 mg kg−1), and arterial blood was sampled at pre‐set intervals. In the analgesic‐potency study, patients were administered intravenous oxycodone (0.1 mg kg−1) 30 min before the end of the surgery, were placed in the postoperative anaesthesia care unit (PACU), and were asked to rate their pain every 10 min using a visual analogue scale (0 = no pain, 10 = most severe pain). On the first occasion that wound pain at rest and during compression was rated as ≥3 or ≥5, respectively, the first blood sample was obtained to determine the MEC. A second blood sample was obtained after titration with 2 mg of oxycodone to yield wound pain <3 at rest and <5 during wound compression, and MEAC was determined. MEC and MEAC were determined again in each patient.
Results
In the population pharmacokinetic study (n = 54), oxycodone plasma concentration over time was well described by a three‐compartment mammillary model. Lean body mass and age were significant covariates for the volume of distribution and metabolic clearance of the pharmacokinetic model of oxycodone, respectively. The analgesic‐potency study (n = 50) showed that the median (95% CI) MEC and MEAC were 31.5 (19.2–42.8) and 74.1 (29.2–128.3) ng ml−1 (first measurements) and 63.4 (15.6–120.1) and 76.1 (32.9–132.7) ng ml−1 (second measurements), respectively.
Conclusions
In major intra‐abdominal open surgery, the MEAC and analgesic potency of oxycodone were 75 ng ml−1 and 60 ng ml−1, respectively.
DOI: 10.1111/bcp.13101
View this article